Compare MHK & KYMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MHK | KYMR |
|---|---|---|
| Founded | 1988 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Home Furnishings | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.6B | 6.8B |
| IPO Year | 1995 | 2020 |
| Metric | MHK | KYMR |
|---|---|---|
| Price | $98.76 | $80.04 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 26 |
| Target Price | ★ $137.78 | $107.72 |
| AVG Volume (30 Days) | ★ 984.9K | 637.3K |
| Earning Date | 04-30-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 5.93 | N/A |
| Revenue | N/A | ★ $39,211,000.00 |
| Revenue This Year | $3.53 | $11.85 |
| Revenue Next Year | $3.10 | $7.79 |
| P/E Ratio | $17.19 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $95.16 | $19.45 |
| 52 Week High | $143.13 | $103.00 |
| Indicator | MHK | KYMR |
|---|---|---|
| Relative Strength Index (RSI) | 32.21 | 48.39 |
| Support Level | $97.69 | $77.78 |
| Resistance Level | $132.71 | $95.90 |
| Average True Range (ATR) | 3.60 | 3.73 |
| MACD | -0.08 | -0.58 |
| Stochastic Oscillator | 25.12 | 49.76 |
Mohawk Industries Inc manufactures a wide range of flooring products, including carpets, rugs, ceramic tile, laminate, wood, luxury vinyl tile, and vinyl flooring. Its operating segments include Global Ceramic, Flooring North America, and Flooring Rest of the World. The company generates maximum revenue from the Global Ceramic segment. Global Ceramic designs, manufactures, sources, distributes and markets a broad line of ceramic, porcelain and natural stone tile products used for floor and wall applications in residential and commercial channels for both remodeling and new construction. Geographically, it derives a majority of its revenue from the United States, while it also operates in Latin America, Europe and Others.
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of differentiated medicines that address health problems and meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, TYK2, and IRAK4.